Coccidioidal meningitis (CM) is a devastating complication of coccidioidomycosis. Since the late 1950s, intrathecal (IT) amphotericin B deoxycholate (AmBd) has been successfully used to treat and often cure this disease, reducing mortality rates from 100% to approximately 30%. The introduction of azoles further revolutionized the treatment of coccidioidal infections. However, IT AmBd remains the only known curative option in the management of CM. While the use of IT AmBd is well described in many articles, few discuss the actual methods behind preparation, titration, and dosing strategies utilized. The practitioners at Kern Medical (Bakersfield, California) have >60 years of experience in the utilization of IT AmBd and the treatment of CM. This article describes the practice experience in the treatment of CM, preparation of IT AmBd, and the different dosing strategies used in regard to route of administration (ie, cisternal, lumbar, ventricular).
Coccidioides species are soil-dwelling fungi that are the causative pathogen of coccidioidomycosis, also known as Valley fever [1] . Infection occurs from inhalation of fungal spores that become airborne from soil in endemic regions (southwestern United States, northwestern Mexico, and parts of Central and South America) [2] . Sixty percent of infections are asymptomatic. Symptomatic primary infection is virtually always respiratory [3] [4] [5] .
Rates of dissemination of primary coccidioidal infections to extrapulmonary sites can range from <1% to as high as 30%-50% [6, 7] . The most common sites of dissemination are to the skin, bone, or to the basilar meninges resulting in coccidioidal meningitis (CM) [8] . Nearly 50% of all cases of disseminated coccidioidal disease result in CM, with most cases occurring within several weeks to months following a primary infection [1] . Upon clinical suspicion of CM, a diagnostic lumbar puncture should be performed. Patients with CM will most often present with fever, headache, neck stiffness, and nausea with vomiting [9] . Hydrocephalus is a common complication. Another complication is cerebral vasculitic infarction [1, 9] .
Historically, CM was an illness that had 100% mortality within 2 years of diagnosis [10] . The advent of amphotericin B deoxycholate (AmBd) in 1957 gave clinicians a promising treatment option; the inception of intrathecal (IT) AmBd reduced CM mortality rates to approximately 30% [1, 11, 12] . The introduction of azoles and, in particular, the triazole fluconazole in 1990 further revolutionized the treatment of coccidioidal infections, including CM, and oral azoles became the mainstay of therapy [7] . However, azoles alone appear to only suppress CM, and thus patients being managed with azole monotherapy require lifelong treatment [13] . At this time, IT AmBd is the only known curative option in the management of CM [14] . The use of IT AmBd is well described, but the actual methods of preparation, titration, and dosing strategies are not elucidated in detail.
Kern Medical (Bakersfield, California) has >60 years of experience in the utilization of IT AmBd. This article describes the practice experience in the treatment of CM, preparation of IT AmBd, and the different dosing strategies used in cisternal, lumbar, and ventricular administration.
Treatment Overview
Nearly all patients diagnosed with CM will be initially treated with oral azole antifungals if there is no contraindication. Fluconazole has remained the primary therapy for >20 years. Originally, fluconazole 400 mg daily was used; however, due to high rates of clinical failure, higher doses ranging from 800 mg to 1200 mg daily are now routinely used for treatment of CM [1, 15] . Patients who continue to experience symptoms or failure to improve cerebrospinal fluid (CSF) findings despite highdose fluconazole monotherapy require changing to a different azole (ie, itraconazole, voriconazole [Vfend] , posaconazole [Noxafil] ), or to initiate IT AmBd [7] . Azole antifungal therapy should be avoided in the first trimester of pregnancy due to teratogenicity; IT AmBd may be considered [7] .
Oral itraconazole 400-600 mg daily has demonstrated notable activity against coccidioidomycosis and has been reported to be as effective as fluconazole [7, 16] . Voriconazole and posaconazole are 2 of the newer oral triazole antifungals and are often reserved for treatment of CM refractory to fluconazole therapy.
Voriconazole prescribed at 4 mg/kg every 12 hours-with adjustments made for serum levels-has been successfully used for rescue therapy after treatment failure with high-dose oral fluconazole [1] . Voriconazole has a favorable pharmacokinetic profile with 96% oral bioavailability, extensive distribution into tissue, and CSF penetration equal to approximately 50% of the plasma concentration [17, 18] .
Posaconazole is available in oral suspension and delayed-release tablet. It is >98% protein bound and has a very large volume of distribution [19] . However, posaconazole has demonstrated poor or variable CSF penetration, which limits its appeal as an initial treatment option for CM, as there may be an increased risk of treatment failure [20] [21] [22] .
Isavuconazonium (Cresemba) was approved by the US Food and Drug Administration in March 2015, making it the newest triazole antifungal marketed in the United States [23] . It is currently approved for the treatment of invasive aspergillosis and mucormycosis, and has shown promise against endemic fungi [23, 24] . Its role in the treatment of coccidioidomycosis is undefined but promising.
Amphotericin B is currently available in the United States in conventional deoxycholate formulations and lipid-based preparations (Ambisome, Abelcet). Although animal model studies on safety and efficacy have been conducted on lipidbased amphotericin B, lack of clinical outcomes data in humans makes it difficult to justify its use in CM [25] [26] [27] . Use at this time would be construed as rescue therapy in cases where all other treatment modalities have been attempted.
Intravenous amphotericin B deoxycholate has poor CSF penetration (approximately 2%-4% of serum level) and is associated with a multitude of drug toxicities [28] . While there is ongoing debate on whether or not intravenous AmBd has a role to play in the treatment of CM, there are not enough comparative data to support either argument [29] . Intrathecal administration is the only proven polyene treatment of CM [30] .
Intrathecal Amphotericin Preparation
At Kern Medical, IT AmBd is prepared with the items listed in Table 1 . Only AmBd and preservative-free (PF) products may be used for IT administration. Intrathecal products must be prepared in certified hood and cleanrooms; aseptic requirements vary depending on state regulations and adherence to US Pharmacopeia chapters 795 and 797 [31] .
Directions for Compounding
Vial 1: Amphotericin B deoxycholate plus methylprednisolone suspension 1. Reconstitute AmBd 50-mg vial with 10 mL sterile water for infusion (PF) for a final concentration of 5 mg/mL of AmBd. Shake well until dissolved. 2. Remove the plastic activator and the non-PF diluent from the upper compartment of the methylprednisolone 40-mg vial. 3. Add 1.6 mL of sterile water for infusion (PF) to the bottom compartment of the methylprednisolone vial and shake briefly to dissolve contents. The resulting suspension will contain 25 mg/mL of methylprednisolone. More-concentrated suspensions will be darker yellow.
Stability. Intact AmBd vials and reconstituted products should be protected from light. Intact AmBd vials should be stored under refrigeration. Reconstituted vials are stable for 24 hours at room temperature and 1 week when refrigerated [32] .
To date, no published data are available for stability of AmBd with methylprednisolone. At Kern Medical, reconstituted vials are kept at room temperature, protected from light, and used within 24 hours. Sterility testing for quality control has returned consistently negative at 24 hours.
Filter. Although the use of filters is often recommended for intrathecal products, the large molecular weight of AmBd molecules precludes the use of filters. An in-line membrane filter may be used for intravenous infusion of AmBd; a filter <1 µm should not be used [32] .
Use With Intrathecal Corticosteroids
Patient tolerability to IT AmBd varies, with some experiencing mild headaches, fevers, nausea, and vomiting or even serious neurotoxicity (chemical meningitis or arachnoiditis) [1, 8] . Use of IT corticosteroids has been cited in multiple descriptive studies to reduce inflammation, headaches, and pleocytosis [33] [34] [35] . However, the effectiveness and resulting clinical outcomes (eg, rate of decline in complement-fixing antibodies in the CSF) of this approach (IT AmBd administration with vs without IT corticosteroids) remains to be proven in randomized controlled trials. In previous in vitro studies, corticosteroids have been shown to contribute to the growth of other fungi [36, 37] . The drug-drug interaction between hydrocortisone and AmBd has been tested against several clinical isolates, including Coccidioides, using the checkerboard titration broth microdilution method. At low (0.3-0.6 mg/mL) to intermediate (0.12-0.2 mg/mL) hydrocortisone concentrations, synergy or indifference against isolates was observed. In contrast, higher concentrations of hydrocortisone (>8 mg/mL) have led to increased AmBd minimum inhibitory concentrations, suggesting antagonism [38] .
At Kern Medical, IT AmBd is given concurrently with 1.25 mg/mL methylprednisolone (equivalent to 6.25 mg/mL hydrocortisone). A 5 mg/mL methylprednisolone (equivalent to 25 mg/mL hydrocortisone) solution is given before or after the IT AmBd plus methylprednisolone suspension depending on the route of administration (see "Routes of Administration" below). Assuming a total CSF volume of 125-150 mL, 25 mg hydrocortisone administered would result in a concentration between 0.167 and 0.2 mg/mL, which is well below the concentration at which hydrocortisone displayed antagonism [38] . Since 1959, IT AmBd has been administered with an IT corticosteroid [11] . In our experience and to our knowledge, an association of treatment failure with the use of IT AmBd and IT hydrocortisone or methylprednisolone has not been observed.
Routes of Administration
Four primary methods of administering IT AmBd into the CSF are used. The observed advantages and disadvantages of each route and the methods employed at our facility are described below. A CSF flow study to assess blocked subarachnoid areas is required before IT therapy [7] . Training is required before performing any of the described procedures below.
Lumbar Administration
Administration of IT AmBd via direct cisternal puncture is historically the preferred route of delivery [7, 16] . Alternative routes include lumbar puncture, lumbar reservoir, and ventricular Ommaya instillation. The lumbar route requires less training, and has demonstrated equivalent efficacy when compared to the more challenging delivery methods [34] . In cases where lumbar punctures become technically challenging, or frequent or prolonged therapy is anticipated, lumbar reservoirs may be employed to simplify IT drug administration and facilitate patient comfort. In our experience, lumbar reservoirs are more prone to infections and occlusion. For practitioners utilizing the lumbar site for drug administration, the patient is placed in a 25°-30° Trendelenburg position to facilitate optimal delivery of the drug into the basal cisterns [34, 39] .
Ventricular Administration
Ventricular Ommaya reservoir is useful when patients develop hydrocephalus, as this route will facilitate removal of CSF and reduce intracranial pressure temporarily. In terms of safety, the risk of clinically significant bleeding via ventricular Ommaya administration is negligible compared with direct cisternal administration. However, the risk of infection is higher. In the puncture of the Ommaya reservoir, a 25-gauge spinal needle rather than a butterfly needle is used to prevent coring of the skin and reservoir. In our experience, this reduced the risk of infection, as well as increased the useful life of the reservoir. The patient is either laid flat or in a semi-sitting position following ventricular administration.
In patients with ventricular shunts to treat hydrocephalus, ventricular Ommaya reservoirs are preferably placed in the opposite ventricle. If the shunt has an on/off valve, it may be turned off 30 minutes prior to and 2 hours after the procedure. These techniques are used to prevent the drug from being siphoned from the central nervous system into the distal shunt.
Cisternal Administration
As CM most often affects the basilar meninges, lumbar and ventricular instillation places the drug farther from the primary site of infection [34] . In contrast, cisternal therapy allows the drug to be administered closest to the basilar meninges [29, 34] . The doses tolerated by cisternal administration tend to be lower than ventricular Ommaya reservoir. In the hands of an experienced physician, cisternal administration is reputedly safe and less troublesome than often assumed. Of note, a rare complication unique to cisternal administration is subarachnoid hemorrhage. Only adequately trained and experienced practitioners should perform this procedure. Patients receiving cisternal AmBd are placed in a 30°-40° Trendelenburg position for 2 hours in an effort to prevent lumbar migration of the drug.
Route of administration of IT AmBd is largely dependent on physician training and patient preference and tolerability. Patients treated via ventricular Ommaya reservoir will require a lumbar puncture to assess efficacy of therapy, as fluid from the ventricles may not accurately reflect disease activity [29, 40] . At our facility, the cisternal and ventricular routes are used most frequently.
For patients receiving IT AmBd through the cisternal route, IT methylprednisolone solution is given prior to IT AmBd. The IT corticosteroid is used as a test injection to ensure that cytotoxic AmBd drug is not injected in the incorrect location. As high precision and technique are required for this maneuver, only experienced physicians should perform this procedure. For patients receiving IT AmBd through the Ommaya reservoir, IT AmBd is given prior to IT methylprednisolone solution. The IT methylprednisolone solution is used to flush IT AmBd drug from the reservoir to the central nervous system.
IT Amphotericin Dosing Schedule and Considerations

Premedication
Similar to intravenous AmBd, intrathecal AmBd has also been associated with nausea, vomiting, fever, back pain, and headache, which usually occur during administration, immediately, or within 15 minutes to 3 hours following administration. At Kern Medical, patients are premedicated 30 minutes before IT AmBd administration with oral metoclopramide 10-20 mg or oral ondansetron 4-8 mg (to prevent nausea and vomiting) and oral diphenhydramine 25-50 mg and oral acetaminophen 650-1000 mg (to prevent fever and headaches). Intramuscular meperidine 25-100 mg may be used to reduce pain. Meperidine is more often needed for postcisternal injection.
Initiation
A dose of 0.1 mg IT AmBd 3 times a week is initially started in all patients regardless of route of administration. This dose is gradually increased by 0.1 mg per week as tolerated (see "Tolerability and Adverse Effects" below). This gradual dose increase helps clinicians discern whether toxicity and side effects are due to dose increase vs frequency of administration. In our experience, a dose increase of >0.1 mg per week in treatment-naive patients has been associated with decreased tolerability and increased toxicity. Dose escalation may be sooner than 0.1 mg per week in treatment-experienced patients or treatment-naive patients who are critically ill.
At our facility the dosing strategy, regardless of baseline patient demographics (eg, age, race, weight), is guided purely by the patient's response and toxicities.
Patients receiving IT AmBd through the ventricular Ommaya reservoir or lumbar routes are generally able to tolerate higher doses of IT AmBd compared with the cisternal route [29] . Some patients have only been able to tolerate doses of 0.2 mg. Tolerable doses as high as 0.9 mg have been observed with the ventricular Ommaya reservoir and 0.8 mg with the cisternal route. Stevens and colleagues observed maximum tolerable doses as high as 1.5 mg through the lumbar route [34] .
Dose Titration and Tapering
The course of treatment is highly variable and must be tailored to each patient's response and tolerability to therapy. Below, the details of the treatment phases proposed by Johnson and colleagues have been further delineated ( Table 2 ) [29] .
In phase I, IT AmBd is given 3 times per week for a minimum of 3 months or until improvement in CSF findings (see "Improvement and Laboratory Findings" below) is observed, whichever period is longer.
In phase II, twice-weekly injections are given for a minimum of 3 months or until improvement in CSF findings is observed, whichever period is longer. This is followed by once-weekly injections for a minimum of 3 months. If CSF findings improve along with a negative complement-fixation titer, patients will enter phase III therapy.
Phase III therapy, also known as the chronic suppressive stage, may last for years. In this stage, as long as CSF findings remain favorable, the frequency of IT AmBd administration will continue to be gradually decreased in frequency from 1 injection per week to as long as 1 injection every 24 weeks. If improvement is not seen, patients will be continued on their current phase and evaluated as required until improvement is seen. If the treatment is deemed successful, and IT AmBd is discontinued, a cisternal or lumbar puncture to reevaluate CSF findings should be performed at least once every 6 months for life. Patients are monitored by clinical evaluation and laboratory findings at the time of drug administration or if they develop new or concerning symptoms. If CSF findings worsen, the patient is considered to be in relapse. Patients with clinical relapse are re-treated like a new patient returning to phase I; however, dose escalation may be faster than 0.1 mg per week if a known tolerable dose has been established in the past. In contrast, Stevens and colleagues propose a different dosing decrement schema [34] .
Missed Doses
For patients who have a significant therapeutic interruption, dose decrease may be warranted based on tolerability, with gradual escalation back to the maximum tolerated dose.
Tolerability and Adverse Effects
The expected side effects for IT administration of AmBd include headache, nausea, and vomiting [29, 34] . Neurotoxicity from IT AmBd consists of ophthalmoplegia, hearing loss, ataxia, paraplegia, neurogenic bladder, and erectile dysfunction. These are almost always temporary, lasting hours. Occasionally, there is permanent neurotoxicity.
In these cases, escalation of dose is not recommended due to risk of permanent neurological deficits, and a decrease of 0.1 mg per dose or a temporary drug holiday may be considered.
Compared to cisternal administration, lumbar and ventricular routes may have a lower rate of headache, nausea, and vomiting. The ability of patients to tolerate IT AmBd varies enormously. Once a maximal tolerated dose has been established for a patient, tolerability for that dose generally remains constant or improves over time, unless the dosing interval is increased significantly. Symptoms usually occur in the first 2-3 hours, and may occur up to 24 hours, after dose administration (Table 3) .
Improvement and Laboratory Findings
Successful treatment is measured in a number of ways including symptomatic improvement and resolution of abnormal physical findings. The predominant way that we measure treatment success is by improvement in the CSF formula, defined as a decrease in pleocytosis over an extended period of time to normal or near-normal, early resolution of hypoglycorrhachia, and a decrement in protein and coccidioidal complement-fixation titers.
CONCLUSIONS
Intravenous amphotericin B deoxycholate was studied in coccidioidal meningitis by Winn and Einstein and found not to be a satisfactory treatment. Intrathecal AmBd was introduced because of this, and produced the first survivals in CM, making it the gold standard of therapy. Although azoles have largely replaced IT AmBd in the management of CM, there are clearly numbers of patients who are refractory to azoles and continue to require alternative therapy. The only demonstratively effective therapy in these patients is IT AmBd. The above information is a guide on how to prepare, administer, and evaluate IT AmBd and its toxicities. 
Notes
